Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
Cabazitaxel-induced ureteritis in metastatic castration-resistant prostate cancer patients: a single center case series 2014-2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zedan Ahmed H, Gade Jesper S, Zieger Karsten Egbert Arnold, Poulsen Mads H, Vejlgaard Anja Schmidt, Fredensborg Filip Lund Hjorth
Аннотация
BACKGROUND: One of the main and effective therapy choices for patients with metastatic castration-resistant prostate cancer (mCRPC) is cabazitaxel (CBZ). Cystitis and hematuria are among the most significant non-hematological adverse events associated with CBZ treatment. But because the prevalence of CBZ-induced ureteritis has not been thoroughly studied, this case series investigation was carried out to emphasize the condition's clinical relevance and potential treatment alternatives.
CASE PRESENTATION: Between June 2014 and May 2024, 354 patients diagnosed with mCRPC were treated with CBZ at the Department of Oncology, Vejle Hospital. A total of 36 patients (10%) exhibited ureteritis-like symptoms, presenting with discomfort in the pelvis, lower abdomen, or flanks, with or without hematuria. Radiological evidence of ureter changes was present in 29 out of 36 individuals (80%), along with hydronephrosis/hydroureter in some patients. Prior to therapy with CBZ, radiation to the pelvis or lower abdomen was documented in 7 out of 36 patients (19%). Various analgesics and dosage modifications were considered for the therapy of CBZ-induced ureteritis, with treatment discontinuation yielding the most favorable results.
CONCLUSION: The onset of ureteritis during CBZ treatment is an underrated side effect in clinical practice. Hematuria and hydronephrosis/hydroureter are the most associated complications. Both analgesics and dosage reduction should be contemplated for management, while therapy cessation may be requisite in certain individuals.
CASE PRESENTATION: Between June 2014 and May 2024, 354 patients diagnosed with mCRPC were treated with CBZ at the Department of Oncology, Vejle Hospital. A total of 36 patients (10%) exhibited ureteritis-like symptoms, presenting with discomfort in the pelvis, lower abdomen, or flanks, with or without hematuria. Radiological evidence of ureter changes was present in 29 out of 36 individuals (80%), along with hydronephrosis/hydroureter in some patients. Prior to therapy with CBZ, radiation to the pelvis or lower abdomen was documented in 7 out of 36 patients (19%). Various analgesics and dosage modifications were considered for the therapy of CBZ-induced ureteritis, with treatment discontinuation yielding the most favorable results.
CONCLUSION: The onset of ureteritis during CBZ treatment is an underrated side effect in clinical practice. Hematuria and hydronephrosis/hydroureter are the most associated complications. Both analgesics and dosage reduction should be contemplated for management, while therapy cessation may be requisite in certain individuals.